Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AZ Electronic Materials directors try to minimize damage

Wed, 10th Apr 2013 16:27

John Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his stake in the company to 118,541 shares. Geoff Wild, the group's Chief Executive Officer, also made a significant purchase, buying 40,000 shares at 268p each. The £107,200 purchase takes his holding to 885,749.A number of other directors also gave the group their backing with purchases of various sizes. The company reported a 2.0% year-on-year decline in revenue to $19.9m for the three months to April 8th, following lower-than-expected sales in its IC Materials division. The company blamed weak performance and an unfavourable product mix in IC Materials, which includes products for use in integrated circuits and devices. Revenue in the division fell 7.0% year-on-year to $123.3m. As a result, the group's EBITDA (earnings before interest, tax, depreciation and amortisation) margin for the three month period was lower than normal, and will be for the year as a whole, it warned. Group revenue for the full year will be around the same levels as last year, the company added. Having lost around 30% of its value on Tuesday, the stock regained 15% the following morning, boosted in part by a rating upgrade from broker UBS. Top Director BuysCentamin (DI) (CEY) Director name: Mr Josef El-RaghyAmount purchased: 500,000 @ 47.80p Value: £239,000AZ Electronic Materials SA (DI) (AZEM) Director name: Mr Geoff WildAmount purchased: 40,000 @ 268.00p Value: £107,200AZ Electronic Materials SA (DI) (AZEM) Director name: Mr John WhybrowAmount purchased: 40,000 @ 254.00p Value: £101,600Synety Group (SNTY) Director name: Mr Simon CleaverAmount purchased: 40,000 @ 125.00p Value: £50,000AZ Electronic Materials SA (DI) (AZEM) Director name: Mr Andrew AllnerAmount purchased: 10,000 @ 255.00p Value: £25,500Verona Pharma (VRP) Director name: Mr Stuart BottomlyAmount purchased: 1,000,000 @ 2.35p Value: £23,500Mission Marketing Group (TMMG) Director name: Mr Chris GoodwinAmount purchased: 60,000 @ 34.00p Value: £20,400Cenkos Securities (CNKS) Director name: Mr Anthony HotsonAmount purchased: 20,000 @ 87.80p Value: £17,560Port Erin Biopharma Investments Ltd (PEBI) Director name: Mr James (Jim) MellonAmount purchased: 200,000 @ 7.50p Value: £15,000Synety Group (SNTY) Director name: Mr Simon CleaverAmount purchased: 10,000 @ 124.80p Value: £12,480Top Director SellsTelecity Group (TCY) Director name: Mr Brian McArthur MuscroftAmount sold: 98,789 @ 888.00p Value: £877,246Close Brothers Group (CBG) Director name: Mr Stephen R HodgesAmount sold: 76,383 @ 1,016.48p Value: £776,418Berendsen (BRSN) Director name: Mr Peter VentressAmount sold: 61,310 @ 782.80p Value: £479,935Spirax-Sarco Engineering (SPX) Director name: Mr Mark E. VernonAmount sold: 18,362 @ 2,608.78p Value: £479,024Amlin (AML) Director name: Mr Richard A HextallAmount sold: 72,533 @ 423.49p Value: £307,170Tarsus Group (TRS) Director name: Mr Douglas EmslieAmount sold: 86,449 @ 230.00p Value: £198,833National Express Group (NEX) Director name: Mr Dean K FinchAmount sold: 69,571 @ 195.89p Value: £136,283Tarsus Group (TRS) Director name: Mr Neville BuchAmount sold: 43,225 @ 230.00p Value: £99,418Tarsus Group (TRS) Director name: Mr Roger PellowAmount sold: 23,084 @ 230.00p Value: £53,093NR
More News
5 Nov 2015 10:50

Verona Pharma Completes Patient Enrolment For RPL554 Studies

Read more
14 Oct 2015 10:40

Verona Pharma: First Patients Dosed In RPL554 Combination Study

Read more
29 Sep 2015 09:18

Verona Pharma rallies on positive drug study results

(ShareCast News) - Shares in Verona Pharma rallied after it announced positive headline data from the third and final part of a clinical study on its RPL554 drug for the treatment of chronic obstructive pulmonary disease. The drug development company said the primary objective of this part of the st

Read more
29 Sep 2015 07:58

Verona Pharma Shares Up 10% On Good RPL554 Study Results

Read more
8 Sep 2015 08:28

Verona Pharma plunges as interim loss widens

(ShareCast News) - Shares in Verona Pharma plunged over 12% early on Tuesday, after the pharmaceutical company posted a wider interim pre-tax loss. The London-listed company, which attributed the wider loss to an increase in research and development spending, saw its pre-tax loss for the six months

Read more
8 Sep 2015 07:23

Verona Pharma Loss Widens On Higher Research And Development Spending

Read more
12 Jun 2015 11:19

LONDON MIDDAY BRIEFING: Greece Remains Optimistic For Debt Deal

Read more
12 Jun 2015 10:27

WINNERS & LOSERS: Petra Diamonds Loses Sparkle On Lower Quality Stones

Read more
12 Jun 2015 09:46

Verona Pharma to launch secondary listing in Germany

AIM-listed drug developer Verona Pharma has carried out a second listing in Germany. The move will be a way of further raising its profile within continental Europe and to increase the potential for investors in German-speaking Europe to trade in the company's shares, it said. The group will be lis

Read more
12 Jun 2015 08:40

Verona Pharma Takes Secondary Listing In Germany (ALLISS)

Read more
11 Jun 2015 07:52

Verona Pharma Begins Phase 2A Dose-Finding Trial Of RPL554 In Asthma

Read more
11 Jun 2015 07:32

LONDON MORNING BRIEFING: Royal Mail Falls, RBS Gains On UK Govt Moves

Read more
11 Jun 2015 05:26

AGM, EGM Calendar - Week Ahead

Read more
10 Jun 2015 15:00

AGM, EGM Calendar - Week Ahead

Read more
10 Jun 2015 05:30

AGM, EGM Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.